

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.*

*This joint announcement appears for information purposes only and is not intended to and does not constitute any offer or invitation to acquire, purchase or subscribe for any securities of the Company, the Offeror or any other entity, nor is it a solicitation of any vote or approval in any jurisdiction. This joint announcement is not for release, publication or distribution, in whole or in part, in any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.*



**CATHAY INTERNATIONAL PHARMA  
MANUFACTURE  
AND DISTRIBUTION (CHINA) LIMITED**  
*(Incorporated in the British Virgin Islands with limited liability)*

**LANSEN PHARMACEUTICAL HOLDINGS LIMITED**  
**朗生醫藥控股有限公司**  
*(incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 503)**

## **JOINT ANNOUNCEMENT**

**(1) PROPOSED PRIVATISATION OF  
LANSEN PHARMACEUTICAL HOLDINGS LIMITED  
BY THE OFFEROR  
BY WAY OF A SCHEME OF ARRANGEMENT  
UNDER SECTION 86 OF THE COMPANIES ACT;  
(2) EFFECTIVE DATE OF THE SCHEME;  
(3) WITHDRAWAL OF  
LISTING OF LANSEN PHARMACEUTICAL HOLDINGS LIMITED;  
AND  
(4) DESPATCH OF CHEQUES**

**Financial Adviser to the Offeror**



**YU MING INVESTMENT MANAGEMENT LIMITED**  
**禹銘投資管理有限公司**

**Independent Financial Adviser to the Independent Board Committee**

**ALTUS CAPITAL LIMITED**

## **INTRODUCTION**

References are made to (i) the scheme document (the “**Scheme Document**”) jointly issued by the Offeror and the Company dated 28 October 2023 in respect of the proposed privatisation of the Company by way of a scheme of arrangement under section 86 of the Companies Act; (ii) the announcement jointly issued by the Company and the Offeror dated 27 November 2023 in relation to the results of the Court Meeting and the General Meeting; and (iii) the announcement jointly issued by the Company and the Offeror dated 15 December 2023 in relation to the sanction of the Scheme by the Grand Court. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Scheme Document, and all times and dates refer to Hong Kong local time and dates.

## **EFFECTIVE DATE OF THE SCHEME**

The Scheme was sanctioned without modification by the Grant Court at the hearing held on 14 December 2023 (Cayman Islands time). A copy of the order of the Grand Court sanctioning the Scheme (the “**Sanction Order**”) was delivered to the Registrar of Companies in the Cayman Islands for registration on 15 December 2023 (Cayman Islands time). All the Conditions as set out in the section headed “The Proposal – Conditions of the Proposal” in the Explanatory Memorandum of Part IV of the Scheme Document have been fulfilled, and accordingly the Scheme became effective on 15 December 2023 (Cayman Islands time).

## **WITHDRAWAL OF LISTING**

The withdrawal of the listing of the Shares on the Main Board of the Stock Exchange is expected to become effective from 9:00 a.m. on Tuesday, 19 December 2023.

## **PAYMENT UNDER THE PROPOSAL**

Cheques for payment of the Scheme Consideration will be despatched to the Scheme Shareholders as soon as possible but in any event on or before Thursday, 28 December 2023.

By Order of the board of directors of  
**Cathay International Pharma Manufacture And  
Distribution (China) Limited**  
**Siu Ka Chi Eric**  
*Director*

By Order of the Board of  
**Lansen Pharmaceutical Holdings Limited**  
**Chen Li**  
*Executive Director*

Hong Kong, 18 December 2023

*As at the date of this joint announcement, the Board comprises Mr. Chen Li being the executive managing Director, Mr. Wu Zhen Tao and Ms. Liu Xuezi being the non-executive Directors, and Mr. Chan Kee Huen, Michael, Mr. Yeung Tak Bun, Allen, Ms. Chan Ching Har, Eliza and Dr. Zhu Xun being the independent non-executive Directors.*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Offeror and Offeror Concert Parties) and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than opinions expressed by the directors of the Offeror and Mr. Wu Zhen Tao in their capacity as such) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.*

*As at the date of this joint announcement, the directors of the Offeror are Mr. Siu Ka Chi Eric and Mr. Patrick Sung. The ultimate beneficial owner of the Offeror is First Lucky Star Trust, the settlor of which is Mr. Wu Zhen Tao, and the beneficiaries include Mr. Wu Zhen Tao and his family members.*

*The directors of the Offeror and Mr. Wu Zhen Tao jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Company) and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Directors in their capacity as such) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.*